May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation
Author Affiliations & Notes
  • M. Saito
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • C. Shiragami
    Ophthalmology, Kagawa University, Kagawa, Japan
  • D. Nagayama
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • T. Iida
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • F. Shiraga
    Ophthalmology, Kagawa University, Kagawa, Japan
  • Footnotes
    Commercial Relationships  M. Saito, None; C. Shiragami, None; D. Nagayama, None; T. Iida, None; F. Shiraga, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 546. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Saito, C. Shiragami, D. Nagayama, T. Iida, F. Shiraga; Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation. Invest. Ophthalmol. Vis. Sci. 2008;49(13):546. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The purpose of this study is to clarify the efficiency of combined therapy with intravitreal bevacizumab injections and photodynamic therapy (PDT) in retinal angiomatous proliferation (RAP) patients.

Methods: : We retrospectively reviewed 10 consecutive eyes (10 patients; 7 men, 3 women) with subfoveal RAP treated with intravitreal bevacizumab injections and PDT. Patients ranged in age from 63 to 89 years, average 78 years. All patients were performed without prior treatment and were followed at least three months (mean, 5 months). For this study using bevacizumab was approved by the Institutional Review Board/Ethics Committee at Fukushima Medical University and Kagawa University. PDT was performed one or two days after the intravitreal bevacizumab (1.25mg) injection. The method of PDT with verteporfin was according to the protocol of the Treatment of AMD with Photodynamic therapy study.

Results: : The mean logMAR best-corrected visual acuity (BCVA) at baseline and 3 months were 0.79 and 0.48, respectively. The mean change in BCVA at 3 months from baseline was an improvement of 3.1 lines. Visual acuity improved in 6 eyes (60%, improved by≥3 lines), remained in 4 eyes (40%). Central retinal thickness significantly decreased from 398 ± 118 to 184 ± 42 (p=0.01). None of all patients needed retreatment at 3 months. There were no complications such as severe vision loss, endophthalmitis, and systemic events.

Conclusions: : Combined intravitreal bevacizumab and PDT for RAP was an effective treatment for maintaining or improving in visual acuity and reducing or eliminating the edema.

Keywords: age-related macular degeneration • photodynamic therapy • retinal pigment epithelium 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×